Close

Aerie

www.aeriepharma.com

Aerie is focused on the development and commercialization of products for prevention and treatment of glaucoma and other eye diseases. A spinout from Duke University School of Medicine, its novel pro-drug technology facilitates development of NCEs for ophthalmology applications. Aerie’s technology improves corneal penetration and duration of action. Ocular hypertension/glaucoma are significant unmet medical needs, and research suggests they are under diagnosed, under treated and their incidence/prevalence increases with age.

Close

Albireo

www.albireopharma.com

Albireo is a spin-out from Astrazeneca. They develop novel therapies that address unmet medical needs in the GI area, specifically chronic constipation. Their lead compound is a non-absorbable therapy for constipation that has been through a successful phase 2a study and is about to start a phase 2b study.

Close

Alder

www.alderbio.com

Alder is an biopharmaceutical company focused on development of novel antibodies that originate from its proprietary platform for the production of antibodies in pichia. Alder's lead antibody is an anti-IL6 antibody which has completed Phase 2 clinical trials in rheumatoid arthritis and cancer. They have a broad pipeline of internally generated antibodies and their platform technology allows antibodies to be made "faster, better and cheaper".

Close

Aptalis Pharma,
previously Axcan Pharma

www.aptalispharma.com

Aptalis Pharma, created by the merger of Axcan Pharma and Eurand N.V., is a leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Close

Avidia^*

Avidia Research Institute develops and manufactures human therapeutic proteins known as avimers. Avidia engineers these avimer drugs against multiple validated and novel targets to address different disease areas, including inflammation, oncology and neurology. In September of 2006 Avidia was acquired by Amgen Inc.

^* Exited Investment

Close

BioCryst

www.biocryst.com

Structure-based drug discovery company with a strong research tradition. Peramivir is marketed to treat influenza, including avian flu. Forodesine could prove to be a targeted and well-tolerated therapy for hematological malignancies, and allopurinol is making progress in gout. The company has announced substantial funding and partnerships with the U.S. Department of Health & Human Services, Green Cross, Shionogi and Mundi Pharma.

Close

Elevation Pharmaceuticals^*

www.elevationpharma.com

Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. The founding team has a successful track record of starting companies and building dedicated teams to develop new drug products that improve patients' lives. Elevation has a disciplined approach to strategic decision-making that helps them stay focused on the path with the highest probability of success. Elevation is executing drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

^* Exited Investment

Close

Epirus

epirusbiopharma.com

Focused on developing and manufacturing a range of biosimilar products in and for emerging markets.

Close

FivePrime

www.fiveprime.com

A pre-clinical stage biotech company discovering innovative protein and antibody therapeutics. Focused on identifying the next generation of protein therapeutics for metabolic disease and supportive care of cancer patients. Most of our information on the genome is long on gene fragments and short on gene function. New technologies will allow us to access a more complete set of full length genes, express the corresponding proteins and identify pharmacologically relevant functions. For chemical genomics to succeed, we must play with the full deck of targets.

Close

FoldRx

www.foldrx.com

Focused on the discovery, development and commercialization of small molecule therapeutics for disease modification of disorders of protein folding and protein homeostasis. The company was founded based on technology developed at the Scripps Institute (San Diego) and the Whitehead Institute (MIT/Cambridge). Diseases of protein folding and protein homeostasis represent a "white space" for therapeutic development driven by recent advances in basic and clinical research. Acquired by Pfizer in 2010.

Close

Galleon

www.galleonpharma.com

The company focuses on the discovery and development of therapeutics that modify the central control of respiration as a route towards medical treatment of sleep apnea, apnea of pre-maturity and drug induced respiratory depression. Medical treatment of sleep apnea, narcotic induced respiratory depression, etc. by direct modulation of central mechanisms represents an innovative strategy to treat significant unmet medical needs. Highly predictable pre-clinical models and a clinical development strategy based on objective physiological endpoints provide a rapid and reliable path to proof of concept as well as to commercialization.

Close

JCR

www.jcrpharm.co.jp

JCR Pharmaceuticals is a Japanese company that focuses on high value follow-on biologics. JCR is a profitable company with fully integrated capabilities, including state of the art production facilities in Japan. Two of JCR’s major commercial products are Growject® (human growth hormone), and a follow-on biologic version of erythropoietin. JCR Pharmaceuticals was established in 1975 and is traded in the Osaka Stock Exchange.

Close

Karos Pharmaceuticals

Karos Pharmaceuticals is a pharmaceutical company focused on bone-related diseases.

Close

MacroGenics

www.macrogenics.com

Product development derived from in-house discoveries and in-licensed candidates in the areas of oncology, inflammation, allergy and infectious diseases. Core capabilities are in antibody and protein engineering, biologics manufacturing, and preclinical and clinical development of biologics. Diversified strategy for creating proprietary immunotherapeutics in areas of unmet medical need, and their Fc engineering technology will be a valuable tool for improving antibody effectiveness. Proven track record for obtaining non-dilutive financing from the NIH.

Close

Otonomy

www.otonomy.com

Otonomy is a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. This field represents a large opportunity as there are no approved drug treatments for the nearly 30 million Americans facing debilitating hearing and balance disorders such as Ménière's disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment, and tinnitus. Additionally, new therapies are required for otitis media since resistance to oral antibiotics is increasing and short-acting locally administered drugs present significant compliance challenges. Otonomy is working in partnership with leading experts in the field of otology to bring new drug therapies to patients suffering with these conditions.

Close

Par Pharmaceutical

www.parpharm.com

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.

Close

Trevi Therapeutics

www.trevitherapeutics.com

Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions. The Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. T111 is an oral extended release opioid with a unique dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus.

Close

Ultragenyx

www.ultragenyx.com

Ultragenyx is a biotechnology startup focused on developing therapeutics with clear mechanisms of action for untreated rare diseases. The company is headed by Emil Kakkis, M.D., Ph.D., former Chief Medical Officer of BioMarin Pharmaceutical.

Close

Virobay

www.virobayinc.com

Semi-virtual company focused on novel treatments for hepatitis C, pain and autoimmune disease. TPG founded the company as a spin-out of assets and team from Celera.

Close

Auxogyn

www.auxogyn.com

Auxogyn is an early stage company focused on advancing treatment in women's reproductive health.

Close

CardioDx

www.cardiodx.com

A molecular diagnostics company that serves cardiologists and their patients by offering clinically validated genomic tests to enhance patient care. Focused on the personalized management of patients with congestive heart failure, rhythm disturbances and atherosclerosis.

Close

Immucor

www.immucor.com

Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.

Close

Genomic Health

www.genomichealth.com

Personalized medicine company focused on large markets in oncology: breast, prostate, colon and lung cancer. Personalized diagnostic tests are needed to influence difficult therapeutic decisions. The ability to collect reliable molecular information from fixed paraffin embedded samples will make this company an industry leader.

Close

Nodality

www.nodalityinc.com

Nodality discovers and develops next generation personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. The company's initial primary areas of focus include hematological malignancies and autoimmune disorders.

Close

NovaSom

www.novasom.com

A proprietary at-home diagnostic technology for Obstructive Sleep Apnea provided directly to patients via a healthcare services model. The NovaSom device is equivalent to current gold standard of overnight sleep study and FDA approved. Medicare reimbursement announced December 2007 and the company is executing a national market launch. Device-enabled services will allow for service models at device margins, while providing a cost savings to payers. OSA is a growing but still under-diagnosed disease category. Reimbursement events and segment growth make this the right time.

Close

Roka

www.rokabio.com

Roka is a molecular pathogen detection company. The company has exclusive access to GenProbe's Transcription Mediated Amplification technology for detecting RNA as applied to Industrial uses and some point of care diagnostic applications. Roka is initially focusing on products to improve safety and detection of pathogens in the food supply, making use of the Panther platform technology developed by GPRO and Roka's proprietary Closed Unit Dose Assay (CUDA) system, providing rapid results with minimal enrichment and sample handling for multiple pathogens. The company is based in New Jersey, with a research and development center in San Diego and is headed by Paul Thomas, previously the CEO of LifeCell.

Close

Veracyte

www.veracyte.com

Personalized medicine focused on molecular cytology. Incubated and co-funded with KPCB and Versant Ventures. Seed capital provided entrepreneurs with time and support to develop investment thesis for new personalized medicine company alongside TPG. Cytopathology is an attractive segment of the pathology market which has not yet seen development of commercial molecular products. Company will leverage proprietary molecular tests to become a channel player in the cytopathology market.

Close

XDx

www.xdx.com

A molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients. Their molecular expression technology is currently being explored to assist with other diseases that involve the immune system.

Close

CSI^*

www.csi360.com

Cardiovascular Systems Inc. (CSI) refined the technology to address the growing market need of providing a safer more effective atherectomy device, and the chance to shift the treatment paradigm to improve the quality of life for the 12 million Americans who suffer from PAD. Its Diamondback 360° Orbital Atherectomy System is protected by 20 patents with 9 additional patents pending. The design, development and OASIS clinical trial testing is complete, with 510K clearance.

^* Exited Investment

Close

Conventus

www.conventusortho.com

Conventus is a medical device company developing a novel, less invasive fixation system for traumatic fractures in the extremities, first targeting fractures of the wrist.

Close

Tandem

www.tandemdiabetes.com

Develops medical devices for insulin administration. Founded in 2006, Tandem is based in San Diego, California.

Close

Vibrynt

www.vibrynt.com

A spin-out of ExploraMed, a venture-backed medical technology incubator. Vibrynt is focused on developing an effective, device-based minimally invasive solution for morbid obesity.

Close

AgraQuest^*

www.agraquest.com

AgraQuest is focused on becoming the leading provider of natural pesticides, fungicides and herbicides. There is a surge in focus on consumer health, and there are several very large market opportunities in the conventional, organic and retail markets for biopesticides. A leading development and commercial position in the market will allow the company to become a platform for further in-licensing and acquisitions. Recapitalization of previous investment at very attractive valuation.

^* Exited Investment

Close

Agria

www.agriacorp.com

A leading Chinese agricultural biotechnology company with sales and operations in five provinces. Proprietary seed corns and a sheep line bred for adaptation to local environment. R&D relationships with key Chinese institutions plus in-house research. Macro factors in China will require AgBio sector to deliver improved performance. Core skills in modern AgBio are analogous to healthcare biotech. TPG leverage enables accelerated company development, and co-investment with TPG Growth China team provides local market know-how.

Close

Alphabet Energy

www.alphabetenergy.com

Alphabet Energy is commercializing an inexpensive waste heat recovery technology developed at the Lawrence Berkeley National Laboratory. The company's thermoelectric approach and materials platform is the only of its kind that lends itself to massive scale at low cost. With products made entirely from sustainable materials, customers may use their waste heat to generate electrical power in the range of microwatts to megawatts.

Close

Amyris

www.amyrisbiotech.com

Company focuses its know-how and proprietary technology on the radical genetic metabolic engineering of micro-organisms for the scale production of designer specialty chemicals, pharmaceuticals and biofuels with superior price/performance characteristics from renewable sources such as sugar. Company is a spin-out of UC Berkeley with headquarters in Emeryville, CA and offices in Sao Paulo, Brazil. Company is pioneering a business model for bringing novel biofuels to market. Macroeconomic trends and societal mandates favor the development and commercialization of renewable technologies. Second generation "designer molecules" overcome limitations of current biofuel molecules and provide marketplace with better price and performance – "no compromise". Significant investment from Gates Foundation in core technology.

Close

Beta Renewables

www.betarenewables.com

Established to exclusively license Chemtex's PROESA® technology into the global marketplace. PROESA® enables production of fermentable sugars from cellulosic biomass in a cost-efficient manner.

Close

Elevance

www.elevance.com

Elevance specializes in using renewable or natural oils (soybean, canola, palm and sunflower oils) to create a variety of specialty chemical products. It offers waxes, functional oils, such as personal care and cosmetics, candles, corrugated coatings, and solvents; industrial and agricultural anti-microbials; and industrial and automobile lubricants, additives and fuels.

Close

Genomatica

www.genomatica.com

Genomatica is a chemical company that commercializes novel bio-manufacturing processes to produce a variety of industrial chemicals that impact all major industries and provide the materials that comprise the world we live in. Genomatica enables the production of sustainable chemicals through a compelling proprietary Integrated BioProcess Engineering Platform and unique capabilities that fundamentally transform the way in which nature can be leveraged to convert low cost feedstocks into high-value chemicals. These sustainable chemical products will benefit the world by reducing dependence on hydrocarbon feedstocks and improving the environment via safe, clean manufacturing processes.

Close

DNAnexus

www.dnanexus.com

DNAnexus is developing a cloud-based distributed storage and computation platform for handling genomics data, with a particular focus on the significant volume of data being generated as sequencing costs continue to rapidly decline.

Close

IMS Health

www.imshealth.com

IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. IMS offers a variety of solutions to help clients understand the marketplace, improve marketing effectiveness and optimize sales productivity. With a presence in more than 100 countries and over 55 years of experience, IMS applies leading-edge technologies to transform billions of pharmaceutical transactions collected from thousands of sources into strategic insights. Interpreted and analyzed by IMS experts, these insights are an unmatched source of trends and perspectives about the pharmaceutical marketplace – precise market intelligence that can be translated into action.

Close

Matrix Laboratories^*

www.matrixlabsindia.com

One of the world's largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs. Based in Hyderabad, India, Matrix was acquired by Mylan in 2006.

^* Exited Investment

Close

moksha8

www.moksha8.com

With offices in Philadelphia and Sao Paulo, moksha8 is focused on becoming the partner of choice for the registration, marketing, sales and distribution of branded therapeutics (patent protected and branded generics) in rest of world markets. Initial focus is on Latin America, especially Brazil and Mexico.

Close

NT Pharma

www.ntpharma.com

A full-range pharmaceutical value chain from research and development, production, sales and marketing to distribution of pharmaceutical and healthcare products. NT Pharma is the only Hong Kong-funded integrated pharmaceutical enterprise capable of providing a "one stop solution" in China.

Close

PatientSafe Solutions

www.patientsafesolutions.com

A patient and nurse-centered company that helps prevent harm and assists in eliminating common errors by providing a complete patient safety solution to hospitals. PatientSafe Solutions' technologies can dramatically improve efficiency, interactivity, and communication in healthcare. PatientSafe Solutions is focused on enabling the nurse and caregivers to spend more time with their patients, significantly improving the quality of patient care and patient satisfaction.

Close

Quintiles

www.quintiles.com

Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries.

Close

ShangPharma

www.shangpharma.com

ShangPharma is a rapidly growing preclinical CRO company with core capabilities based on strengths in organic chemistry. It is the second largest preclinical CRO in China, with major clients such as Lilly, Glaxo and Pfizer.

Close

WIL Research^*

www.wilresearch.com

WIL Research Laboratories is a contract research organization (CRO) that provides an interdisciplinary approach to toxicology, pharmacology, metabolism, and bioanalytical services to the pharmaceutical, biotechnology, chemical, agricultural, veterinary, and food and consumer products industries.

^* Exited Investment